- Event: Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care (February 25, 2021)
- In Law360, Margaux Hall Examines Drug Commercialization and Market Access Strategies in Light of Drug Pricing Regulatory Uncertainty Under the Biden Administration
(February 16, 2021)
- 2022 Medicare Advantage and Part D Final Rule Includes Update to Star Ratings System and Implementing Coverage and Transparency Measures (February 5, 2021)
-
Medicare Expands Coverage of “Breakthrough” Medical Devices and Codifies “Reasonable and Necessary” Standard
(January 21, 2021)
- Health Care Co-Chairs Address Key Issues Facing Health Payers in 2021
(January 8, 2021)
- In Law360, Tom Bulleit Analyzes 2021 Health Policies Under the Biden Administration (January 5, 2021)
- In Law360, Attorneys Evaluate 2021 IPO Market (January 5, 2021)
- The 2020 Election and Health Care (December 15, 2020)
- In Bloomberg Law, Tom Bulleit Discusses New “Stark” and Anti-Kickback Rules for Value-Based Arrangements (November 25, 2020)
- In Law360, Health Care Attorneys Examine State Drug Pricing Reforms (November 25, 2020)
- In Law360, Health Care Attorneys Address President Trump’s Executive Order on International Reference Pricing for Medicare Drugs (September 29, 2020)
- In Law360, Tom Bulleit Examines Trump’s Latest Drug Pricing Executive Order (September 15, 2020)
Cookie Settings
